ORANO MED: A BIOTECH ON THE RISE

Over 200 employees in France and the United States

Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, is developing a new generation of targeted cancer therapies based on the unique properties of lead-212 (212Pb). Better known as lead-212 alpha therapy, this approach destroys cancer cells while limiting the impact on surrounding healthy cells. It opens up promising prospects for patients who have only limited treatment options.

Orano Med is currently conducting several clinical trials in patients with different types of cancer to evaluate the efficacy of its drug candidates.

Orano Med is unique in that it is the first biotech company to control the entire value chain of lead-212-based targeted alpha therapy: from pre-clinical research to clinical development, and from production to distribution of drugs.

Read our comic book!

Pre-clinical research

Orano Med has its own pre-clinical laboratories
to accelerate the transition of its molecules to clinical trials in humans.

  • 3 R&D laboratories in France and the United States;
  • 18 patented inventions;
  • in-house expertise allowing the complete development of new molecules.

Clinical development

11 drug candidates are currently
in development, including:

4 in clinical development :

  • AlphaMedixTM : neuroendocrine tumors,
  • 212Pb-GRPR : solid tumors such as breast cancer, prostate cancer and glioblastoma,
  • 212Pb-CEA-PRIT : colorectal cancer and other solid tumors,
  • 212Pb-DARPin-DLL3 (MP0712) : small cell lung cancer and others.

3 strategic partners:

Production and distribution

To guarantee broad and secure access to treatment, Orano Med has an integrated industrial platform, overing the entire value chain, from access to raw materials to distribution of the final drug to hospitals in less than 24 hours. An essential capability given that the half-life of lead-212 is 10.6 hours:

  • ATEF (France): the world’s first industrial platform dedicated to the production of thorium-228, the precursor of lead-212;
  • 2 ATLabs in France and the United States: pharmaceutical laboratories dedicated to the large-scale production of treatments radiolabeled with lead-212.

Comic book

  1. Three characters (a scientist, an engineer wearing safety equipment, and a manager in a suit) appear to be wondering. Speech bubble: "What are we going to do with this?" — The Orano Group has 22,000 drums of purified thorium-232 from former mining activities.
  2. The suited manager raises his finger, he has an idea. Speech bubble: “I've got an idea! We'll extract lead-212 from this raw material.” — Lead-212 is a promising radioisotope in nuclear medicine, particularly in the fight against cancer. This idea led to the creation of Orano Med in 2009.
  3. The scientist looks through a microscope while the manager explains. A diagram illustrates the targeting of cancer cells. Speech bubble: "This approach is called lead-212 targeted alpha therapy." — The properties of lead-212, combined with other components, make it possible to target and destroy cancer cells while limiting the impact on surrounding healthy cells.
  4. The scientist points to a diagram showing the three components of the treatment: lead-212, chelator and targeting vector. Speech bubble: "This is how we can develop lead-212-based treatments." — Orano Med has a team of researchers who develop treatments targeting different types of cancer. Once the research has reached a sufficient stage of maturity, the clinical team, made up of physicians, takes over to conduct clinical trials in humans.
  5. The manager in a suit looks at a world map while considering how to ensure the international distribution of the medicines. Speech bubble: "Now, how will Orano Med produce these treatments on a large scale?" — Orano Med is developing an industrial infrastructure that will enable the supply of treatments to tens of thousands of patients worldwide, with deliveries within 24 hours.
  6. The engineer presents a model of the ATEF facility. Speech bubble: "We are building ATEF, the world's first facility to produce thorium-228 on an industrial scale." — Thorium-228, a precursor of lead-212, will help meet global demand for targeted alpha therapy.
  8. The three characters come together to conclude the story. Manager’s speech bubble: "Orano Med’s ambition is to develop a broad range of cancer treatments." Scientist’s speech bubble: "That’s amazing! From nuclear technology to medical research: what an adventure!"

For more information, visit www.oranomed.com